Cargando…
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening,...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312327/ https://www.ncbi.nlm.nih.gov/pubmed/18446196 http://dx.doi.org/10.1371/journal.pone.0002043 |
_version_ | 1782152572154413056 |
---|---|
author | Stevens, Wendy Kamali, Anatoli Karita, Etienne Anzala, Omu Sanders, Eduard J. Jaoko, Walter Kaleebu, Pontiano Mulenga, Joseph Dally, Len Fast, Pat Gilmour, Jill Farah, Bashir Birungi, Josephine Hughes, Peter Manigart, Olivier Stevens, Gwynn Yates, Sarah Thomson, Helen von Lieven, Andrea Krebs, Marietta Price, Matt A. Stoll-Johnson, Lisa Ketter, Nzeera |
author_facet | Stevens, Wendy Kamali, Anatoli Karita, Etienne Anzala, Omu Sanders, Eduard J. Jaoko, Walter Kaleebu, Pontiano Mulenga, Joseph Dally, Len Fast, Pat Gilmour, Jill Farah, Bashir Birungi, Josephine Hughes, Peter Manigart, Olivier Stevens, Gwynn Yates, Sarah Thomson, Helen von Lieven, Andrea Krebs, Marietta Price, Matt A. Stoll-Johnson, Lisa Ketter, Nzeera |
author_sort | Stevens, Wendy |
collection | PubMed |
description | BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons. |
format | Text |
id | pubmed-2312327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-23123272008-04-30 Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials Stevens, Wendy Kamali, Anatoli Karita, Etienne Anzala, Omu Sanders, Eduard J. Jaoko, Walter Kaleebu, Pontiano Mulenga, Joseph Dally, Len Fast, Pat Gilmour, Jill Farah, Bashir Birungi, Josephine Hughes, Peter Manigart, Olivier Stevens, Gwynn Yates, Sarah Thomson, Helen von Lieven, Andrea Krebs, Marietta Price, Matt A. Stoll-Johnson, Lisa Ketter, Nzeera PLoS One Research Article BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18–60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons. Public Library of Science 2008-04-30 /pmc/articles/PMC2312327/ /pubmed/18446196 http://dx.doi.org/10.1371/journal.pone.0002043 Text en Stevens et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Stevens, Wendy Kamali, Anatoli Karita, Etienne Anzala, Omu Sanders, Eduard J. Jaoko, Walter Kaleebu, Pontiano Mulenga, Joseph Dally, Len Fast, Pat Gilmour, Jill Farah, Bashir Birungi, Josephine Hughes, Peter Manigart, Olivier Stevens, Gwynn Yates, Sarah Thomson, Helen von Lieven, Andrea Krebs, Marietta Price, Matt A. Stoll-Johnson, Lisa Ketter, Nzeera Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title | Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title_full | Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title_fullStr | Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title_full_unstemmed | Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title_short | Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials |
title_sort | baseline morbidity in 2,990 adult african volunteers recruited to characterize laboratory reference intervals for future hiv vaccine clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2312327/ https://www.ncbi.nlm.nih.gov/pubmed/18446196 http://dx.doi.org/10.1371/journal.pone.0002043 |
work_keys_str_mv | AT stevenswendy baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT kamalianatoli baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT karitaetienne baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT anzalaomu baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT sanderseduardj baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT jaokowalter baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT kaleebupontiano baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT mulengajoseph baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT dallylen baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT fastpat baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT gilmourjill baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT farahbashir baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT birungijosephine baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT hughespeter baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT manigartolivier baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT stevensgwynn baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT yatessarah baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT thomsonhelen baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT vonlievenandrea baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT krebsmarietta baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT pricematta baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT stolljohnsonlisa baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT ketternzeera baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials |